Yellowish Sclera (Jaundice) – A Complete Patient Guide

Overview

Jaundice is the medical term for a yellow discoloration of the skin, mucous membranes, and the whites of the eyes (the sclera). The yellow hue results from an accumulation of bilirubin—a yellow‑orange pigment produced when red blood cells break down. While many people associate jaundice only with liver disease, it can arise from any condition that interferes with bilirubin production, transport, or elimination.

Who it affects: Jaundice can occur at any age, from newborns (physiologic jaundice) to older adults with chronic liver disease. In adults, the most common causes are liver‑related (e.g., hepatitis, alcoholic liver disease, non‑alcoholic fatty liver disease), hemolysis, and biliary obstruction.

Prevalence: In the United States, an estimated 4‑5 % of the adult population will develop some form of clinically significant jaundice over a lifetime, most commonly secondary to chronic liver disease. Neonatal jaundice affects up to 60 % of full‑term infants and 80 % of preterm infants during the first week of life (CDC, 2023).

Symptoms

Jaundice manifests as a constellation of signs that reflect the underlying process. The sclera are often the first place patients notice a color change because they are highly visible.

• Yellowish sclera – a distinct amber or golden tint to the whites of the eyes; may appear before skin discoloration.
• Yellow skin – starts on the face and neck, spreading downward.
• Dark urine – bilirubin excreted in the urine turns it amber.
• Pale, clay‑colored stools – reduced bilirubin reaching the intestines.
• Itching (pruritus) – bile salts deposited in the skin can cause severe discomfort.
• Fatigue and weakness – common in chronic liver disease.
• Abdominal pain or fullness – especially in the right upper quadrant if the liver or gallbladder is involved.
• Loss of appetite & nausea.
• Weight loss – may accompany chronic disease.
• Fever, chills, or rigors – suggest infection (e.g., cholangitis).

Causes and Risk Factors

How bilirubin is normally processed

Red blood cells live about 120 days; when they die, hemoglobin is broken down into heme, then into biliverdin, and finally into unconjugated (indirect) bilirubin. This insoluble form travels to the liver bound to albumin, where it is conjugated (made water‑soluble) and excreted into bile. Disruption at any step can raise serum bilirubin and cause jaundice.

Major categories of causes

1. Pre‑hepatic (hemolytic) jaundice – excessive breakdown of red cells:
   • Hereditary spherocytosis, G6PD deficiency, sickle‑cell disease.
   • Autoimmune hemolytic anemia.
   • Severe infections (malaria, sepsis).
2. Hepatic (parenchymal) jaundice – liver’s ability to conjugate or secrete bilirubin is impaired:
   • Viral hepatitis (A, B, C, D, E).
   • Alcoholic liver disease.
   • Non‑alcoholic fatty liver disease (NAFLD) – now affecting ~25 % of U.S. adults.
   • Cirrhosis of any etiology.
   • Drug‑induced liver injury (e.g., acetaminophen overdose, certain antibiotics, herbal supplements).
   • Genetic disorders (Gilbert’s syndrome, Crigler‑Najjar, Dubin‑Johnson).
3. Post‑hepatic (obstructive) jaundice – blockage of bile flow:
   • Gallstones.
   • Pancreatic head carcinoma.
   • Strictures from previous surgery or chronic pancreatitis.
   • Primary sclerosing cholangitis, primary biliary cholangitis.
   • Parasites (e.g., liver flukes) in endemic regions.

Risk factors

• Excessive alcohol consumption (>14 drinks/week for men, >7 for women).
• Obesity and metabolic syndrome – major contributors to NAFLD.
• Chronic viral hepatitis infection (especially hepatitis B & C).
• Family history of hereditary hemolytic or bilirubin‑metabolism disorders.
• Use of hepatotoxic medications (e.g., high‑dose acetaminophen, isoniazid, methotrexate).
• Prior biliary surgery or trauma.
• Living in or traveling to regions with endemic parasitic infections.

Diagnosis

Clinical evaluation

Doctors begin with a thorough history (onset, associated symptoms, medication use, alcohol intake, travel) and a physical exam focusing on the pattern of yellowing, liver size, and signs of chronic liver disease (spider angiomata, palmar erythema, ascites).

Laboratory tests

• Total and direct (conjugated) bilirubin – distinguishes pre‑hepatic (mostly indirect) from hepatic/post‑hepatic (direct) elevations.
• Liver function panel – ALT, AST, alkaline phosphatase (ALP), gamma‑GT, albumin, PT/INR.
• Complete blood count – detects hemolysis (low hemoglobin, high reticulocyte count, elevated LDH).
• Haptoglobin – low in hemolysis.
• Viral hepatitis serologies – HBsAg, anti‑HBc, anti‑HCV.
• Autoimmune markers – ANA, SMA, LKM‑1 if autoimmune hepatitis is suspected.
• Iron studies and ceruloplasmin – if Wilson’s disease or hemochromatosis is a concern.

Imaging

• Abdominal ultrasound – first‑line to assess gallstones, biliary duct dilation, liver texture.
• CT or MRI – detailed evaluation of masses, pancreatic head lesions, or vascular anatomy.
• MRCP (magnetic resonance cholangiopancreatography) – non‑invasive view of the biliary tree.

Special procedures

• Endoscopic Retrograde Cholangiopancreatography (ERCP) – diagnostic and therapeutic for biliary obstruction.
• Liver biopsy – definitive for unexplained chronic hepatitis or cirrhosis.

Treatment Options

Addressing the underlying cause

• Hemolytic disorders – steroids or immunosuppressants for autoimmune hemolysis; avoidance of triggers (e.g., certain foods for G6PD deficiency); transfusion in severe anemia.
• Viral hepatitis – direct‑acting antivirals for HCV (cure rates >95 %); nucleos(t)ide analogs for chronic HBV.
• Alcohol‑related liver disease – complete abstinence, counseling, and possibly corticosteroids for alcoholic hepatitis.
• NAFLD/NASH – weight loss (≥7‑10 % body weight), exercise, control of diabetes and hyperlipidemia; emerging agents (e.g., obeticholic acid) under study.
• Biliary obstruction – stone extraction (ERCP or laparoscopic cholecystectomy), stenting, or surgery for tumors.
• Drug‑induced injury – immediate discontinuation of the offending agent; N‑acetylcysteine for acetaminophen toxicity.
• Genetic syndromes – Gilbert’s syndrome usually requires no treatment; severe cases like Crigler‑Najjar may need phototherapy or liver transplantation.

Symptomatic care

• Pruritus – cholestyramine, rifampin, or naltrexone; antihistamines for mild itch.
• Vitamin K supplementation – when prolonged PT/INR threatens bleeding.
• Phototherapy – standard for neonatal jaundice; reduces indirect bilirubin.

Lifestyle modifications

• Limit alcohol and avoid hepatotoxic substances.
• Adopt a Mediterranean‑style diet (rich in fruits, vegetables, whole grains, healthy fats).
• Maintain a healthy weight (BMI < 25 kg/m²).
• Stay physically active – at least 150 minutes of moderate‑intensity aerobic exercise per week.

Living with Yellowish Sclera (Jaundice)

Daily management tips

• Monitor bilirubin levels as advised by your provider, especially after changes in medication or diet.
• Protect skin – moisturize to relieve itching; avoid hot showers that can exacerbate pruritus.
• Hydration – drink plenty of water; adequate fluids help the kidneys clear bilirubin.
• Nutrition – small, frequent meals that are low in saturated fat; incorporate omega‑3 fatty acids (fish, flaxseed) to support liver health.
• Medication safety – use a medication list; consult pharmacists before adding over‑the‑counter drugs or supplements.
• Vaccinations – stay current with hepatitis A and B vaccines, influenza, and COVID‑19 to reduce additional liver stress.
• Regular follow‑up – liver ultrasound or elastography every 6–12 months if you have chronic liver disease, per AASLD guidelines.
• Support – join patient groups (e.g., American Liver Foundation) for education and emotional support.

Prevention

• Vaccinate against hepatitis A & B.
• Practice safe sex and avoid sharing needles to reduce hepatitis C transmission.
• Limit alcohol – no more than moderate intake (≤1 drink/day for women, ≤2 for men) or abstain if liver disease is present.
• Maintain a healthy weight – diet, exercise, and regular medical screening for diabetes and hyperlipidemia.
• Use medications responsibly – follow dosing instructions, avoid unnecessary long‑term NSAIDs or acetaminophen >3 g/day.
• Travel precautions – avoid raw or undercooked fish in endemic areas for liver flukes; practice good hand hygiene.

Complications

If the underlying cause is not treated, persistent hyperbilirubinemia can lead to serious sequelae:

• Cirrhosis – irreversible scarring, portal hypertension, and risk of hepatocellular carcinoma.
• Coagulopathy – impaired synthesis of clotting factors, increasing bleeding risk.
• Hepatic encephalopathy – neurocognitive changes due to toxin buildup.
• Kidney injury (hepatorenal syndrome) in advanced liver disease.
• Septic complications – especially in obstructive jaundice where bacterial overgrowth can cause cholangitis.
• Fetal complications – uncontrolled maternal jaundice during pregnancy can cause pre‑term birth or fetal loss.

When to Seek Emergency Care

References

• Mayo Clinic. “Jaundice.” Updated 2023. https://www.mayoclinic.org
• CDC. “Neonatal Jaundice.” 2023. https://www.cdc.gov
• American Association for the Study of Liver Diseases (AASLD). “Guidelines for the Diagnosis and Management of NAFLD.” 2022.
• World Health Organization. “Hepatitis B Fact Sheet.” 2022.
• Cleveland Clinic. “Biliary Obstruction.” 2023. https://my.clevelandclinic.org
• National Institutes of Health. “Gilbert Syndrome.” 2021.